Talus Bioscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Talus Bioscience is an early-stage biotech leveraging a proprietary platform to make the regulome, a previously hidden layer of gene control, accessible for drug discovery. Its technology combines AI-designed chemical libraries, high-throughput functional proteomics, and machine learning models to identify and drug transcription factors and other regulatory proteins implicated in disease. The company is advancing an internal pipeline of first-in-class programs in oncology and immunology while also exploring strategic partnerships to expand its reach.

OncologyImmunologyRare DiseaseCardiometabolic

Technology Platform

Integrated AI/ML platform combining AI-designed chemical libraries, high-throughput functional proteomics to measure thousands of regulome targets in live cells, and foundation models trained on massive compound-target interaction data to discover drugs for transcription factors and other regulatory proteins.

Opportunities

The regulome represents a vast, untapped reservoir of novel drug targets implicated in cancer, autoimmune, and rare diseases, offering a multi-billion dollar market for first-in-class therapies.

Talus's integrated platform also creates a partnership opportunity to provide unique insights to other biopharma companies seeking to drug difficult targets or understand disease mechanisms.

Risk Factors

The core scientific risk is the extreme difficulty of drugging transcription factors and validating that platform hits translate into safe, effective medicines.

Financially, as a pre-revenue startup, the company faces significant burn rate and dilution risk as it scales its platform and pipeline without near-term income.

Competitive Landscape

Talus competes in the crowded AI-drug discovery space against companies like Recursion, Exscientia, and Relay Therapeutics, but differentiates by focusing specifically on the live-cell regulome. It also faces competition from biotechs targeting specific transcription factors (e.g., Foghorn Therapeutics) and from large pharma internal efforts. Its unique integration of functional proteomics at scale is a key differentiator.

More companies in CRISPR / Gene Editing →More companies in United States →